Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00865670 | To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions | PHASE1 | COMPLETED | 38 | — | — | Aug 1, 2003 | Sep 1, 2003 | Mar 29, 2017 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Azithromycin Monohydrate 600mg Tablets |
| 2 | ACTIVE_COMPARATOR | Zithromax (azithromycin dihydrate)600mg Tablets |
| Name | Type | Description |
|---|---|---|
| Azithromycin Monohydrate 600 mg Tablets | DRUG | - |
| Zithromax (azithromycin dihydrate) 600 mg Tablets | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening Exclusion Criteria: * Positive test results for HIV or hepatitis B or C * Treatment for drug or alcohol dependence * Female subjects who are pregnant or ...